Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Civil Rights Groups Sue Trump Administration Over Childcare Funding Freeze and Influencer's Role 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DOJ Rescinds Anti-Weaponization Fund Ahead of Todd Blanche Senate Confirmation Vote 
Juan Orlando Hernandez Seeks Dismissal of Honduras Charges After Trump Pardon 
Peru Court Frees Former President Ollanta Humala After Conviction Overturned 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Judge Approves Anthropic’s $1.5 Billion AI Copyright Settlement With Authors 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Lebanon Lawyers Seek Probe Into Banker Over Alleged Netanyahu Dinner in Washington 
Airbus Joins Air India A320 Altitude Drop Probe 
SEC Moves to Dismiss Insider Trading Case Against Trump-Pardoned Terren Peizer 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
FCC Moves to Ban Imports of Foreign Military-Grade Drones Over Security Risks 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizer’s RSV vaccine, Abrysvo, which GSK claimed infringed on its own RSV shot, Arexvy. The two pharmaceutical giants filed to drop the case with prejudice in Delaware federal court, preventing it from being refiled. Neither company has commented publicly or disclosed if a settlement was reached.
GSK originally sued Pfizer in 2023, alleging that Abrysvo violated patents related to antigen technology used in Arexvy. According to GSK, Pfizer’s RSV vaccine development began in 2013, several years after GSK had started work on its version. Pfizer denied the allegations, arguing that GSK’s patents were invalid. In a related case, a UK court sided with Pfizer and invalidated similar GSK patents in 2023.
The U.S. Food and Drug Administration has approved RSV vaccines from GSK, Pfizer, and Moderna (NASDAQ:MRNA). Arexvy, GSK’s RSV shot, currently leads U.S. sales in this growing vaccine market. RSV, or respiratory syncytial virus, causes mild cold-like symptoms but can lead to serious respiratory illness, especially in infants and older adults.
The patent battle over RSV vaccines highlights intensifying competition in the global vaccine market. Despite dropping this particular case, legal tensions remain between GSK and Pfizer. GSK has another ongoing U.S. lawsuit claiming Pfizer’s COVID-19 vaccine, Comirnaty, infringes on its patented technology.
As leading pharmaceutical firms compete for dominance in respiratory vaccines, patent disputes are likely to continue. RSV vaccine sales are expected to grow as global demand rises, making this a critical area for innovation and legal scrutiny.
